Inovio Pharmaceuticals Stock News

It was certainly a possibility in 2020.

It was certainly a possibility in 2020.

These companies wouldn't be worth a second look, even in a less volatile market.

These companies wouldn't be worth a second look, even in a less volatile market.

LABU - A Compelling Biotech Trade

Inovio's stock price is back near pre-Covid levels. It is nearing commercialization of its HPV dysplasia vaccines. It might even still succeed in the Covid vaccine game.

Following the recent pullback in Inovio Pharmaceuticals Inc.'s (NASDAQ:INO) shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securitie

The heavy selling pressure might have exhausted for Inovio (INO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in r

Both companies could become notable latecomers in the coronavirus vaccine market.

Vontobel Holding Ltd. raised its position in shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) by 69.6% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 189,556 shares of the biopharmaceutical company’s stock after acquiring an additional 77,800 shares during the period. Vontobel Holding Ltd.’s holdings in Inovio Pharmaceuticals were worth $1,357,000 as of its most recent […]

Inovio Pharmaceuticals Inc. (NASDAQ:INO) shares, rose in value on Friday, 12/17/21, with the stock price up by 8.51% to the previous days close as strong demand from buyers drove the stock to $6.50. Actively observing the price movement in the last trading, the stock closed the session at $5.99, falling within a range of $5.90 Inovio Pharmaceuticals Inc. (NASDAQ: INO) Has Outstanding Potential Read More »

NEW YORK , Dec. 17, 2021 /PRNewswire/ -- The ongoing pandemic is causing renewed concerns as new variants are becoming more prominent. As an example, test positivity rates in New York City have doubled in just three days, Dr. Jay Varma , a top health advisor to Mayor Bill de Blasio , tweeted Thursday. According to data provided by the CDC on Wednesday, New York and New Jersey are the two states with the most rapid spread of the Omicron variant. To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC''s national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. In the meantime, restrictions for private businesses have become more strict. Todos Medical Ltd. (OTC: TOMDF ), Pfizer Inc. (NYSE: PFE ), Johnson & Johnson (NYSE: JNJ ), Inovio Pharmaceuticals, Inc. (NASDAQ: INO ), Vaxart, Inc. (NASDAQ: VXRT ) As a result of the most recent surge, schools like New York University and Cornell University have canceled in-person events and shifted finals online.

The stock price of Inovio Pharmaceuticals, a biotechnology company focused on synthetic DNA products for treating cancers and infectious diseases, has seen a large fall of 17% over the last month, whi

Jaw-dropping sales growth doesn't always tell investors the full story.

Los Angeles, USA, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Glioblastoma Pipeline Analysis | Clinical Trials Report 2021 | DelveInsight There are approximately 150+ key companies developing Glioblastoma therapies. The companies with Glioblastoma drug candidates in the most advanced stage are Kintara Therapeutics, Diffusion Pharmaceuticals, Celgene Corporation, Bio-Thera Solutions. DelveInsight''s " Glioblastoma Pipeline Insight " report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Glioblastoma pipeline landscapes. It comprises Glioblastoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Glioblastoma pipeline products. Some of the key takeaways from the Glioblastoma Pipeline Report Major companies such as Celgene Corporation, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Accendatech, Pfizer, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others are developing potential drug candidates to improve the Glioblastoma treatment scenario.